Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis

Chen, Jun; Zhang, Xixi; Millican, R. Carl; Sherwood, Jennifer; Martin, Seán T.; Jo, Hanjoong; Yoon, Young Sup; Brott, Brigitta C.; Jun, Ho Wook

doi:10.1016/j.addr.2021.01.005

Cited by 90 publications

(75 citation statements)

References 375 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the cardiovascular disease-related deaths, 85% are caused by heart attacks and strokes, and the most significant cause of the two diseases is the blockage of blood vessels. Atherosclerotic lipid-laden plaques are the major etiology factors for blood vessel blockage, and as these plaques are stacked inside the sub-endothelial space (i.e., the intima), the walls of the vessel become narrow and physically interfere with the blood flow [ 2 , 3 ]. Since atherosclerosis is asymptomatic until the occurrence of remarkable phenomena, early detection is difficult.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases

Lee

2021

IJMS

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of death worldwide, and its prevalence is increasing due to the aging of societies. Atherosclerosis, a type of chronic inflammatory disease that occurs in arteries, is considered to be the main cause of cardiovascular diseases such as ischemic heart disease or stroke. In addition, the inflammatory response caused by atherosclerosis confers a significant effect on chronic inflammatory diseases such as psoriasis and rheumatic arthritis. Here, we review the mechanism of action of the main causes of atherosclerosis such as plasma LDL level and inflammation; furthermore, we review the recent findings on the preclinical and clinical effects of antibodies that reduce the LDL level and those that neutralize the cytokines involved in inflammation. The apolipoprotein B autoantibody and anti-PCSK9 antibody reduced the level of LDL and plaques in animal studies, but failed to significantly reduce carotid inflammation plaques in clinical trials. The monoclonal antibodies against PCSK9 (alirocumab, evolocumab), which are used as a treatment for hyperlipidemia, lowered cholesterol levels and the incidence of cardiovascular diseases. Antibodies that neutralize inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17, and IL-12/23) have shown promising but contradictory results and thus warrant further research.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Since atherosclerosis is asymptomatic until the occurrence of remarkable phenomena, early detection is difficult. As such, the prognosis is poor in most cases, which directly links to the high mortality rates [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases

Lee

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Recent advancements in biotechnology and medicine allow nanoparticles to be used intensively in biomedical applications, including production and improvement of delivery systems for bioactive molecules or chemotherapeutic agents, diagnosis and therapy of a variety of diseases and tissue engineering [ 1 , 2 , 3 , 4 , 5 , 6 ]. Nanoparticles fabricated for drug delivery reduce their side effects, while enhancing drug efficiency and improving drug release and pharmacological properties [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

“…There is a continuing interest and challenge in biocompatible and biodegradable nanoparticle manufacturing from polymers in the biomedical industry [ 9 , 10 , 11 ]. Polymeric nanoparticles are colloidal particles that can be produced by using natural or synthetic polymers [ 2 ]. Among the polymers, the most recognized biopolymers are polysaccharides which are naturally derived compounds as chains of carbohydrate molecules [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Resveratrol-Loaded Levan Nanoparticles Produced by Electrohydrodynamic Atomization Technique

et al. 2021

View full text Add to dashboard Cite

Considering the significant advances in nanostructured systems in various biomedical applications and the escalating need for levan-based nanoparticles as delivery systems, this study aimed to fabricate levan nanoparticles by the electrohydrodynamic atomization (EHDA) technique. The hydrolyzed derivative of levan polysaccharide from Halomonas smyrnensis halophilic bacteria, hydrolyzed Halomonas levan (hHL), was used. Nanoparticles were obtained by optimizing the EHDA parameters and then they were characterized in terms of morphology, molecular interactions, drug release and cell culture studies. The optimized hHL and resveratrol (RS)-loaded hHL nanoparticles were monodisperse and had smooth surfaces. The particle diameter size of hHL nanoparticles was 82.06 ± 15.33 nm. Additionally, release of RS from the fabricated hHL nanoparticles at different pH conditions were found to follow the first-order release model and hHL with higher RS loading showed a more gradual release. In vitro biocompatibility assay with human dermal fibroblast cell lines was performed and cell behavior on coated surfaces was observed. Nanoparticles were found to be safe for healthy cells. Consequently, the fabricated hHL-based nanoparticle system may have potential use in drug delivery systems for wound healing and tissue engineering applications and surfaces could be coated with these electrosprayed particles to improve cellular interaction.

show abstract

“…Nanomedicine is a multidisciplinary and cutting-edge field holding the potential to provide solutions for the prevention, diagnosis, and treatment of ASCVD ( Hu et al, 2020 ). Generally, the nanomaterials (NMs) used in nanomedicine can be categorized as zero-dimensional [nanoparticles (NPs)], one-dimensional (nanotubes, nanofibers, nanorods, and nanowires), two-dimensional (nanofilms), or three-dimensional (bulk materials) NMs ( Chen et al, 2021a )with diameters ranging from 1 to 100 nm. In the biomedical world, larger structures (1–1,000 nm) are also considered NMs ( Bejarano et al, 2018 ; Lozano et al, 2018 ; Hu et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Advances in Nanomaterials for Injured Heart Repair

Guo

Yang

Wang

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Atherosclerotic cardiovascular disease (ASCVD) is one of the leading causes of mortality worldwide. Because of the limited regenerative capacity of adult myocardium to compensate for the loss of heart tissue after ischemic infarction, scientists have been exploring the possible mechanisms involved in the pathological process of ASCVD and searching for alternative means to regenerate infarcted cardiac tissue. Although numerous studies have pursued innovative solutions for reversing the pathological process of ASCVD and improving the effectiveness of delivering therapeutics, the translation of those advances into downstream clinical applications remains unsatisfactory because of poor safety and low efficacy. Recently, nanomaterials (NMs) have emerged as a promising new strategy to strengthen both the efficacy and safety of ASCVD therapy. Thus, a comprehensive review of NMs used in ASCVD treatment will be useful. This paper presents an overview of the pathophysiological mechanisms of ASCVD and the multifunctional mechanisms of NM-based therapy, including antioxidative, anti-inflammation and antiapoptosis mechanisms. The technological improvements of NM delivery are summarized and the clinical transformations concerning the use of NMs to treat ASCVD are examined. Finally, this paper discusses the challenges and future perspectives of NMs in cardiac regeneration to provide insightful information for health professionals on the latest advancements in nanotechnologies for ASCVD treatment.

show abstract

Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis

Cited by 90 publications

References 375 publications

Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases

Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases

Resveratrol-Loaded Levan Nanoparticles Produced by Electrohydrodynamic Atomization Technique

Advances in Nanomaterials for Injured Heart Repair

Contact Info

Product

Resources

About